He considers African American reticence about participation in biomedical research and examines race and health disparities in light of advances in genomic sequencing technology. James Doucet-Battle begins with a historical overview of how diabetes has been researched and framed racially over the past century, chronicling one company’s efforts to recruit African Americans to test their new diabetes risk-score algorithm with the aim of increasing the clinical and market value of the firm’s technology. But has science gone so far in racializing diabetes as to undermine the search for solutions? In a rousing indictment of the idea that notions of biological race should drive scientific inquiry, Sweetness in the Blood: Race, Risk, and Type 2 Diabetes(University of Minnesota Press, 2021) provides an ethnographic picture of biotechnology’s framings of Type 2 diabetes risk and race and, importantly, offers a critical examination of the assumptions behind the recruitment of African American and African-descent populations for Type 2 diabetes research.
Decades of data cannot be ignored: African American adults are far more likely to develop Type 2 diabetes than white adults.
0 kommentar(er)
